secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADMA BIOLOGICS, INC. (ADMA)
CIK:        0001368514
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0001140361-23-023899
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADMA Biologics Q1 revenue $56.9M (+96% YoY); first-time positive Adjusted EBITDA $2.5M
--------------------------------------------------------------------------------

- Total revenues $56.9M, up 96% YoY; net loss narrowed to $6.8M from $25.0M.
- First-time positive Adjusted EBITDA of $2.5M, ahead of forecast; FY2023 revenue guidance raised to >$220M.
- Gross margin improved to 29.0% from 12.6%; legacy low-margin BIVIGAM inventory nearly depleted.
- ASCENIV production scaled to 4,400L; expects margin expansion and plant capacity improvement.
- Cash $69.2M; working capital $227.4M; strategic review ongoing with Morgan Stanley.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1368514/000114036123023899/0001140361-23-023899-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1368514/000114036123023899/brhc20052575_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-023899

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer